Enlivex Therapeutics (FRA:1BT) Other Long-Term Liabilities : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Enlivex Therapeutics Other Long-Term Liabilities?

Enlivex Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2023 was €0.00 Mil.

Enlivex Therapeutics's quarterly other long-term liabilities increased from Jun. 2023 (€-0.00 Mil) to Sep. 2023 (€0.00 Mil) and increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Enlivex Therapeutics's annual other long-term liabilities declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€-0.00 Mil) but then increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Enlivex Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Enlivex Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Other Long-Term Liabilities Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Enlivex Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Enlivex Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (FRA:1BT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ENLV:USA ENLV:Israel

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (FRA:1BT) Headlines

No Headlines